Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives

Sellamuthu Subbanna Gounder1, Radha Kodiappan2, Soon Choy Chan3, Abhi Veerakumarasivam4 and Baskar Subramani1*

1Nichi-Asia Life Science Sdn Bhd, Selangor, Malaysia
2Perdana University Royal College of Surgeon Ireland, Perdana University, 43400 Serdang, Selangor Darul Ehsan, Malaysia
3Perdana University School of Foundation Studies (PUSFS), Perdana University, 43400 Serdang, Selangor Darul Ehsan, Malaysia
4Sunway Institute for Healthcare Development, Sunway University, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia

*Corresponding author: Dr. Baskar Subramani, Nichi-Asia Life Science Sdn Bhd, (786331-D) 57, Block F, Jalan Teknology 3/9 Bistari “De” Kota, Kota Damansara PJU 5, 47810 Petaling Jaya Selangor Darul Eshan, Malaysia, Tel: +603-6142-1920/21, Fax: +603-6142, E-mail: baskar@niscell.com

Abstract
Liver cirrhosis is a leading cause of mortality worldwide. Although treatable by liver transplantation, quality of life is unlikely to drop in all the patients after five years. The shortage of matching donors and the high risk of surgical-associated complications further limits the therapeutic potential of transplantation. Since adult stem cells can be effectively differentiated into hepatocyte-like cells, the potential to translate this utility as a therapeutic alternative has been considerably explored. The bone marrow serves as an ideal source of Hematopoietic Stem Cells (HSCs) and Mesenchymal Stem Cells (MSCs). Although both of these cells have in vivo ability to generate hepatocytes-like cells, MSCs are more potent. Autologous and allogeneic adult stem cell-based therapies have shown promising results in restoring liver function in cirrhosis patients. However, there is still a lack of consensus with regards to the optimum standardization of stem cell source, type, dosage, and mode of transplantation. Many variations exist across the different clinical studies conducted and this hampers the mainstream clinical realization of adult stem cell-based therapy for liver cirrhosis. Thus, this article attempts to review and consolidate the various cellular source, type, dose, and mode of delivery permutations across the various clinical studies published to date.

Introduction
Liver cirrhosis is an end-stage pathological condition that results from a range of chronic liver diseases. Many chemicals, viruses and toxic substances have been associated with the development of cirrhosis. It is usually characterized by hepatocyte necrosis, defense, and collagen deposition contributes to fibrosis that ultimately lead to the cumulative loss of liver function. In addition, liver cirrhosis is also characterized by the formation of regenerative nodules that eventually replace the entire liver architecture, leading to decreased blood flow throughout the liver. Besides reduced quality of life, individuals with liver cirrhosis also have an increased risk of liver cancer. As a result, liver cirrhosis accounts for more than one million worldwide deaths annually and an even greater disease-associated morbidity burden. The treatment of cirrhosis is designed to hinder further liver damage, treat cirrhotic complications and prevent liver cancer. Unfortunately, various therapeutic-associated limitations have led to the increase in fatality rates over the years. At present, the only effective therapeutic option is Orthotopic Liver Transplantation (OLT). OLT for liver cirrhosis results in a 5-year survival rate of about 70%. However, the efficacy and widespread application of OLT is hampered by the shortage of matching donors, surgery-associated morbidities and risk of graft-rejection. These limitations have driven researchers and clinicians to develop...
Stem cell therapy has emerged as an attractive therapeutic approach for a myriad of life-threatening diseases in recent years. Specifically, cell-based therapies for liver cirrhosis have successfully progressed from preliminary laboratory and pre-clinical evaluations. Several studies have demonstrated that both adult and non-residential liver stem cells have the ability to differentiate into hepatocyte-like cells or bile duct epithelial cells, and more pertinently restore liver function [7-11]. The mechanistic action of stem cell-mediated restoration of liver function in liver cirrhosis has not been fully defined. However, several mechanisms have been proposed. Some studies suggest the presence of autocrine signalling, whereby the transition of stem cells into hepatocytes-like cells is induced by the secretion of Hepatocyte Growth Factor (HGF) [12,13]. In contrast, some studies postulate that paracrine signaling mediates liver regeneration through revascularization and enhancing repopulation of endogenous cells in necrotic tissue through the secretion of various cytokines and growth factors [6,14]. Stem cells may also attenuate liver fibrogenesis by inhibiting the activation of hepatic stellate cells (cells responsible for the secretion of extracellular matrix components that include collagen and adhesive glycoproteins) via stem cell-derived cytokines and growth factors such as IL6, IL10, TNFa and HGF. For example, HGF directly suppresses hepatic stellate cell activation by blocking the Extracellular Signal-Regulated Kinase (ERK) and Transforming Growth Factor (TGF-β) signaling pathways [15-17].

Various sources and types of stem cells have been identified as potential cell-based therapeutics for the management of liver failure or cirrhosis (Figure 1). Embryonic stem cells and induced-pluripotent stem cells have been shown to be most potent in the context of their ability to differentiate into hepatocyte-like cells in both, animals and humans. However, genomic instability, oncogenic risk and ethical issues continue to limit their widespread clinical translation [18,19]. In contrast, the application of multipotent adult stem cells has been identified as being safe with no significant ethical constraints. Various obstacles such as limited knowledge in stem cell biology, insufficient cell number and technological challenges surrounding in vitro expansion that previously hampered the utility of these cells have been supplanted in recent years. As a result, a number of studies involving adult stem cell-based therapy of liver cirrhosis patients have shown promising results without significant clinical impediments [20].

Adult stem cells, which include Hematopoietic Stem Cells (HSCs), Programmed Progenitor Cells (PPS) and stromal or Mesenchymal Stem Cells (MSCs) are primarily generated from the bone marrow. Adult stem cells have also been identified in specific niches in many organs and tissues. These stem cells have the ability to differentiate into many types of cells and tissues, including neurons, cardiac myocytes, hepatocytes and pancreatic cells by Preston, et al. 2003. Numerous clinical studies have demonstrated that the use of bone marrow-derived stem cells is not only safe but also results in significant improvement in minimizing disease progression. Therefore, autologous bone marrow-derived stem cells have been used to treat end-stage liver failure or cirrhosis [20-22]. Due to their unique self-renewal and multi-differentiation potential, HSCs were thought to have the most regenerative potential. This was supported by findings that bone marrow-derived CD34+ HSCs have the ability to restore liver function within a short term follow-up [21]. However, several recent pre-clinical and clinical studies have demonstrated that MSCs from bone marrow have greater regenerative effects than HSCs. These cells have endodermal lineage differ-

Figure 1: Autologous and allogenic adult stem cell-based therapy for liver cirrhosis. Multipotent adult stem cells, including HSCs and MSCs (collectively known as MNCs) are potent therapeutic agents in the management of liver cirrhosis. Autologous transplantation involves the transfer of adult stem cells derived from the patient’s own bone marrow back into the patient via intravenous, intrasplenic or the hepatic artery. While, a similar route of administration is applied in allogenic therapy, the MSCs are obtained from umbilical cord or blood of a healthy donor.
entiation potential and thus can differentiate into hepatocyte-like cells. These findings have shifted the liver cirrhosis therapeutic research focus to the transplantation of bone marrow-derived MSCs [13,23]. Nevertheless, recent evidence suggest that co-transplantation of an enriched multipopulation of stem cells, instead of any specific adult stem cells, has a greater impact on therapeutic outcome on end stage liver disease [24].

Apart from the use of autologous stem cells derived from the bone marrow, allogeneic stem cells, specifically MSCs, have been identified as a potential therapeutic tool in treating liver cirrhosis. Most of these allogeneic stem cells are isolated from the umbilical cord blood, Wharton’s jelly, amniotic fluid, dental pulp and adipose tissues. Despite their hypoimmunogenic and regenerative properties, not many clinical studies have been conducted to demonstrate the clinical utility of allogeneic MSC in treating liver cirrhosis patients [25]. However, a recent clinical study suggests that umbilical cord-derived MSC transplantation has the potential to improve liver function without any noticeable side-effects in patients [26].

Despite the growing evidence pertaining to the enormous therapeutic potential of stem cells in liver cirrhosis management, the seamless clinical translation from bench to bedside is still impeded by multiple factors. Many variations across different studies hamper the determination of optimum standards for stem cell source, type, dosage, and mode of transplantation. The lack of a generalized consensus will continue to result in divergent experimental protocols in current and future clinical studies. These variations affect the ability of the researchers to make direct and objective comparisons that unfortunately further inhibits the mainstream clinical realization of adult stem cell-based therapy for liver cirrhosis. Thus in this article, we attempt to review and highlight the various cellular source, type, dose, and mode of delivery permutations across the clinical studies published to date.

### Bone Marrow-Derived Mononuclear Cells (BM-MNCs) in Autologous Liver Cirrhosis Therapy

Numerous studies have revealed that bone marrow-derived stem cells (HSCs and MSCs) are safer and have great therapeutic potential to treat diseases such as Parkinson, myocardial infarction, acute renal failure, knee and spinal cord injuries [27,28]. The percentage of HSCs and MSCs in human bone marrow is approximately 1 in 1 × 10⁶ cells and 1 in 5 × 10⁴ cells, respectively. Thus the MSC population is about 5-fold smaller than that of HSCs [29]. These stem cells, collectively known as Mononuclear Cells (MNCs) have the potential to differentiate into hepatocyte-like cells in both, in vitro and in vivo conditions [20].

Several clinical trials have suggested that the trans-fusion of autologous BM-MNCs effectively promote liver regeneration by reducing fibrosis, improve liver function and survival rates [30,31] (Table 1). These extracellular matrix remodeling Matrix Metalloproteinases (MMPs) exert their anti-fibrotic effects by inducing apoptosis in hepatic stellate cells [32,33] the cells primarily responsible for the initiation and progression of hepatic fibrosis [2]. The therapeutic utility of BM-MNC has been largely evaluated in liver cirrhosis patients associated with hepatitis B, hepatitis C, alcoholic liver diseases, and decompensated and biliary duct liver cirrhosis. Child-Pugh Score (CPS) and Model for End-Stage Liver Disease (MELD) are the two important scoring systems widely used to evaluate the prognosis of patients with liver diseases [9,10], including cirrhosis. The CPS considers five clinical factors, three of which assess the synthetic function of the liver (i.e., total bilirubin level, serum albumin level and international normalized ratio, or INR) and 2 of which are based on clinical assessments (i.e., degree of ascites and hepatic encephalopathy). The MELD is a newer scoring system that has been developed to determine priority for liver transplantation. Disease progression is calculated based on the MELD score. For example, if the MELD score decreases from the baseline before therapy, the therapy is deemed to be successful. These

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Dose</th>
<th>Route</th>
<th>Sample size (n)</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM</td>
<td>Single median dose/1 × 10⁶</td>
<td>Hepatic artery</td>
<td>10</td>
<td>Increased serum albumin; Decreased bilirubin</td>
<td>[22]</td>
</tr>
<tr>
<td>BM</td>
<td>Single median dose/240-1027 × 10⁶</td>
<td>Intravenous</td>
<td>22</td>
<td>Increased serum albumin; Decreased bilirubin and ascites</td>
<td>[34]</td>
</tr>
<tr>
<td>BM</td>
<td>Single median dose/5.2 × 10⁹</td>
<td>Peripheral vein</td>
<td>9</td>
<td>Increased serum albumin; Decreased CPS</td>
<td>[20]</td>
</tr>
<tr>
<td>BM</td>
<td>Single median dose/0.48-1.48 × 10⁶/kg body weight</td>
<td>Peripheral vein</td>
<td>10</td>
<td>Increased serum albumin; Decreased ascites</td>
<td>[11]</td>
</tr>
<tr>
<td>BM</td>
<td>Single median dose/8 × 10⁶</td>
<td>Peripheral vein</td>
<td>5</td>
<td>Increased serum albumin and protein; Decreased prothrombin time</td>
<td>[35]</td>
</tr>
<tr>
<td>BM</td>
<td>Single median unspecified dose</td>
<td>Hepatic artery</td>
<td>30</td>
<td>Increased serum albumin; Decreased CPS</td>
<td>[72]</td>
</tr>
</tbody>
</table>

Table 1: Therapeutic applications of bone marrow derived-stem cells in liver cirrhosis patients.
factors or parameters are generally used to determine liver function qualitatively and quantitatively.

A study in 2007 showed that the administration of an average of $100 \times 10^6$ BM-MNCs through the hepatic artery in patients ($n = 10$) with liver cirrhosis was practically safe and able to stimulate an increase in albumin levels and decrease of bilirubin levels; suggesting an improvement in liver function [22]. In addition, patients who received transfusions with the highest amounts of BM-MNCs had the most significant improvement in liver function [22]. In addition, patients who received transfusions with the highest amounts of BM-MNCs had the most significant improvement in liver function [22]. These improvements were seen in patients with hepatitis B-associated liver cirrhosis ($n = 22$) [34]. Patients in this study showed good clinical outcome. The serum albumin levels increased while the bilirubin levels and ascites decreased. In another study involving nine liver cirrhosis patients treated with a single median dose of $5.2 \pm 0.63 \times 10^9$ BM-MNCs via the peripheral vein, it was found that the patients showed improved serum albumin levels and CPS within a short follow-up period of 24 weeks [20]. A recent study revealed that a single dose of $0.48-1.48 \times 10^9$/kg body weight of BM-MNCs via the peripheral vein showed significant improvement in the outcome of 10 patients with hepatitis B-associated liver cirrhosis without causing any serious side-effects [12]. Besides increasing serum albumin levels and diminishing ascites, the MRI scans of these patients showed that their liver volume increased by 80%. The follow-up study involving alcoholic liver cirrhosis patients ($n = 5$) infused with a single median peripheral vein injection of $8.0 \pm 7.3 \times 10^9$ BM-MNCs showed remarkable improvement in serum albumin, protein and prothrombin levels [35].

Although, these BM-MNC clinical studies have shown promising liver function improvement effects, the magnitude of efficacy and overall Quality of Life Index (QLI) varied significantly between studies. The inconsistencies observed in the measured clinical end points are associated with the differences in treatment protocols, including the dose and duration of treatment. For instance, a recent clinical trial of BM-MNC transplantation in patients with decompensated alcoholic liver disease failed to expand the population of hepatic progenitor cells or improve liver function [36]. However, these could be due to the number of BM-MNC ($0.47 \pm 0.15 \times 10^9$) used in this study which is lower than any other studies [22,36]. It has been estimated that at least $28 \times 10^9$ healthy hepatocytes or about 1-5% of the total liver mass are essential for normal liver function [37-39]. Due to the lack of understanding of the exact mechanism by which BM-MNC induces liver regeneration, it is very hard to predict the number of BM-MNCs that are required to restore physiological liver function. Many clinical trials have proposed that by increasing the number of BM-MNCs within a safe therapeutic window, patient prognosis improves. Thus, one dose of $2 \times 10^8$ BM-MNC per kg body weight could be considered as an optimum dose for future studies. Based on existing evidence, there are no significant variations between the routes of administration [40].

### Bone Marrow-Derived Hematopoietic Stem Cells (BM-HSCs) in Autologous Liver Cirrhosis Therapy

Growing evidence suggest that bone marrow-derived HSCs have the plasticity to differentiate into non-hematopoietic lineage cells, such as endothelial cells, fibroblasts, myocytes, nephrons and hepatocytes [30,40,41]. In fact, these bone marrow-derived stem cells are known to play a primary role in liver regeneration. The increased mobilization of bone marrow-derived stem cells to the liver has been shown to exert beneficial effects in rodent cirrhosis model systems [42-44]. The paradigm of stem cell-based therapy has now shifted towards the enrichment of specific bone marrow-derived stem cells, particularly CD34+, CD45+ and CD133+ HSCs obtained from the peripheral blood [20,45]. The enrichment of peripheral BM-HSCs can be achieved by either purification of aspirated BM or the mobilization of HSCs using Granulocyte Colony Stimulating Factor (G-CSF). However, the administration of G-CSF has been fraught by several complications, such as a high risk of tumor progression and spontaneous rupture of the spleen [46,47]. The direct aspiration of bone marrow and the enrichment of hematopoietic cell populations in the peripheral blood by either sorting or ex vivo expansion of HSCs has been shown to be a safer therapeutic approach.

The transplantation of BM-HSCs at a dose range of between $1 \times 10^6$ to $2 \times 10^8$ cells in liver cirrhosis patients either through the portal vein, peripheral vein, or he-

### Table 2: Therapeutic applications of bone marrow-derived HSCs in liver cirrhosis patients.

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Dose</th>
<th>Route</th>
<th>Sample size (n)</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM-HSC</td>
<td>Single median dose/5 × 10^8</td>
<td>Peripheral vein</td>
<td>10</td>
<td>Increased serum albumin; Decreased CPS</td>
<td>[20]</td>
</tr>
<tr>
<td>BM-HSC</td>
<td>Single median dose/2 × 10^8</td>
<td>Portal vein (n = 3); Hepatic artery (n = 2)</td>
<td>5</td>
<td>Increased serum albumin; Decreased bilirubin and ascites</td>
<td>[50]</td>
</tr>
<tr>
<td>BM-HSC</td>
<td>Single median dose/2.3 × 10^8</td>
<td>Hepatic artery</td>
<td>9</td>
<td>Increased ALT, AST; Decreased CPS, serum bilirubin and ascites</td>
<td>[51]</td>
</tr>
<tr>
<td>BM-HSC</td>
<td>Single median dose/range between 1 × 10^6 - 2 × 10^8</td>
<td>Portal vein/hepatic artery</td>
<td>5</td>
<td>Increased serum albumin; Decreased serum bilirubin</td>
<td>[52]</td>
</tr>
</tbody>
</table>
The hepatic artery has been considered safe and tolerable [48,49]. Following these safety profile reports, a number of clinical studies have demonstrated the possible beneficial effects of bone marrow-derived HSCs in patients with liver cirrhosis (Table 2). A pilot study involving 10 patients with hepatitis B- or C-associated liver cirrhosis showed that a single median dose of about 5 × 10^6 BM-HSCs via the peripheral vein significantly improved albumin levels and CPS [20]. In a parallel study, chronic liver failure patients who underwent portal vein (n = 3) and hepatic artery (n = 2) infusion of a single median dose of 2 × 10^6 autologous BM-HSC showed an improvement without any complications or side effects [50]. These patients’ serum albumin levels increased while the serum bilirubin levels decreased. On the contrary, in four patients with decompensated cirrhosis, a single dose of 3-10 × 10^6 of BM-HSC infused via the hepatic artery resulted in severe adverse effects including nephropathy and hepatorenal syndrome [49]. Due to the failure of the treatment, the study was terminated prematurely.

In another study, the infusion of BM-HSCs at a dose of 2.3 × 10^8 cells via hepatic artery in nine patients showed desirable outcomes without any adverse effects [51]. These patients showed significant improvement in serum Alanine Transaminase (ALT), and Aspartate Transaminase (AST) levels one week post-infusion. Twelve weeks after infusion, the serum bilirubin and CPS levels were significantly reduced and ascites improved in 7 out of 9 patients. In another clinical study, the feasibility and the efficacy of CD34+ HSC infusion in five chronic liver disease patients was assessed [52]. In this study, patients were injected with a single dose of HSCs ranging between 1 × 10^6 to 2 × 10^8 cells via either the portal vein or hepatic artery. The Quality of Life Index (QULI) was found to be considerably improved up to 6 months post-infusion. Patient serum bilirubin levels only began to increase 18 months after the infusion. This clinical study provides evidence that infusion of CD34+ HSCs is relatively safe without any complications or side effects in the long term. Despite the diverse range of BM-HSCs (1 × 10^6 to 2.3 × 10^8 cells) per infusion, almost all the clinical studies have shown that these stem cells have the ability to restore liver function. However, the long term therapeutic effect in mitigating disease progression is rather limited. Thus, BM-HSC-based therapy could be considered as a first-line therapy before OLT or long-term multiple infusion therapy.

### Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) in Autologous Liver Cirrhosis Therapy

Mesenchymal stem cells possess unique biological properties. They are not only able to differentiate into a broad range of mesodermal lineages but also other embryonic lineages. These cells amplify their clinical utility through other innate properties such as their self-renewing capacity, homing and migration ability, immunosuppressive potential, and paracrine effects such as anti-inflammation, anti-apoptosis, anti-fibrosis/anti-scarring (matrix remodeling) and angiogenesis [28,53]. These features make MSCs the most potent and preferred therapeutic tool in regenerative medicine. Several experimental and pre-clinical studies demonstrate that MSCs seem to have a crucial role in the improvement of liver regeneration in many liver disease models, especially in cirrhosis. Most clinical studies utilizing MSCs to treat liver cirrhosis are in phase I or II trials. Much of the focus is to evaluate the safety, feasibility and efficacy of the treatment (Table 3). While a number of clinical trials have used various sources of MSCs for liver cirrhosis treatment, BM-MSC-based therapy has successfully entered into phase III trials. Since phase III clinical trials involve a large number of patients, they provide more robust evidence of the potency of BM-MSCs in treating liver cirrhosis.

### Table 3: Therapeutic applications of bone marrow-derived MSCs in liver cirrhosis patients.

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Dose</th>
<th>Route</th>
<th>Sample size (n)</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM-MSC</td>
<td>Single median dose/ unspecified</td>
<td>Intrahepatic and intrasplenic</td>
<td>40</td>
<td>Increased serum albumin; Decreased CPS, MELD score, bilirubin and ascites</td>
<td>[40]</td>
</tr>
<tr>
<td>BM-MSC</td>
<td>Single median dose/30-40 × 10^6</td>
<td>Peripheral vein</td>
<td>4</td>
<td>Improved liver function and Decreased MELD score</td>
<td>[48]</td>
</tr>
<tr>
<td>BM-MSC</td>
<td>Single median dose/31.73 × 10^6</td>
<td>Peripheral or the portal vein</td>
<td>8</td>
<td>Increased serum albumin; Decreased MELD score, serum creatinine, prothrombin, and bilirubin</td>
<td>[10]</td>
</tr>
<tr>
<td>BM-MSC</td>
<td>Single median dose/ unspecified</td>
<td>Hepatic artery</td>
<td>572</td>
<td>Increased serum albumin; Decreased MELD score and serum bilirubin</td>
<td>[54]</td>
</tr>
<tr>
<td>BM-MSC</td>
<td>Single median dose/1 × 10^6 per kg body weight</td>
<td>Intravenous</td>
<td>25</td>
<td>Improved serum albumin; Decreased prothrombin, bilirubin and MELD score</td>
<td>[55]</td>
</tr>
<tr>
<td>BM-MSC</td>
<td>Single median dose/10 × 10^6</td>
<td>Intrasplicnic</td>
<td>20</td>
<td>Increased serum albumin; Decreased serum bilirubin, AST, ALT, prothrombin and INR</td>
<td>[56]</td>
</tr>
<tr>
<td>BM-MSC</td>
<td>Single median dose/1.9 × 10^6</td>
<td>Peripheral vein</td>
<td>27</td>
<td>No significant improvement</td>
<td>[9]</td>
</tr>
</tbody>
</table>
liver failure, the transfusion of a single median dose of BM-MSCs through the intrasplenic (n = 10) and intrahepatic (n = 10) veins showed significant improvement in albumin and CPS levels as well as the MELD score. Ascites and bilirubin corresponding levels were also reduced [41]. There was a positive therapeutic effect of autologous BM-MSCs implantation in patients with end-stage liver disease associated with hepatitis or cryptogenic cirrhosis [10]. The liver function of patients in this study showed remarkable improvement after a cycle of peripheral or portal vein infusion of 30-50 million MSCs. The study suggests that the clinical outcome is not influenced by the routes of administration. In 2011, a larger clinical study evaluated the short- and long-term efficacy, and prognosis of autologous BM-MSCs in 572 liver failure patients [54]. This study measured the efficacy of BM-MSC transfusion through the hepatic artery 3 weeks and 192 weeks after transplantation. However, the number of BM-MSCs infused was not mentioned. The reduction of the MELD score and serum bilirubin levels coupled with the increase in serum albumin levels provides evidence that patient liver function improved significantly as compared to the control group.

A subsequent study in 2012 assessed the potential effects of hepatocyte-like cells differentiated from BM-MSCs prior to infusion as compared to undifferentiated BM-MSCs in 25 liver cirrhosis patients [55]. While this study showed that the intravenous infusion of 1 × 10^6 cells per kg body weight is safe and improves liver function, the clinical outcomes between both treatment groups did not vary. The patients’ prothrombin and serum albumin levels increased, while the bilirubin levels and MELD score decreased 3-9 months after infusion. Recently, a pilot study was conducted to evaluate the safety and efficacy of autologous BM-MSCs in 20 liver cirrhosis patients. These patients received an intrasplenic injection of 10 × 10^6 BM-MSCs and were monitored for 10 months [56]. This study further validated that autologous BM-MSC transfusion significantly improves liver function, whereby the serum bilirubin, AST and ALT levels, prothrombin time and International Normalized Ratio (INR) decreased, while serum albumin levels increased. No serious adverse events were reported. The dosage of 1 × 10^6 cells per kg body weight also appears to be optimum.

In contrast, a randomized control study showed that ex vivo expanded BM-MSCs did not significantly improve the average liver function of 27 decompensated cirrhosis patients [9]. These patients were transfused with a median dose of 1.95 × 10^6 ex vivo expanded BM-MSCs via a peripheral vein and were followed up for 12 months. Based on the clinical outcomes, it was suggested that the autologous MSCs transplantation via peripheral vein may not be a viable therapeutic option for decompensated cirrhosis patients. It is suggested that either the hepatic artery or the portal vein may be a more ideal route of administration for BM-MSC transfusion in decompensated cirrhosis patients.

### Allogeneic Stem Cells in Liver Cirrhosis Therapy

Although, autologous transplantation of stem cells has many advantages, under certain circumstances, it might not be a viable option. A major limitation is the ability to harvest sufficient numbers of potent stem cells, especially from elderly patients. Besides age-dependence, many patients who would benefit from stem-cell based therapy suffer from diseases that deplete their stem cell niches [57]. Hence for these patients, allogeneic stem cells become the most viable option. The clinical utility of allogeneic MSCs has been explored in many cell-based therapies. These cells have the ability to evade graft-versus-host rejection due to their unique immunosuppressive and immunosurveillance capacities. HSCs do not have the same immunomodulatory ability [58]. These MSCs can be isolated from umbilical cord or cord blood, placenta and amniotic fluid. They have been shown to be more potent than BM-MSCs [59-62]. With respect to the involvement of MSCs in liver regenerative medicine, many studies have demonstrated that the infusion of human umbilical cord- or cord blood-derived MSCs via a vein or multiple direct injections into the liver effectively relieves liver cirrhosis and improves the survival rate in rodent models. These studies also suggest that multiple infusions show better clinical outcomes as compared to a single infusion of allogeneic MSCs [62-65].

Based on this pre-clinical evidence, a considerable number of clinical studies have provided sufficient evidence to suggest that the administration of allogeneic MSCs is safe and ameliorates liver function in patients with end-stage liver diseases (Table 4). An open labeled

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Dose</th>
<th>Route</th>
<th>Sample size (n)</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>UC-MSC</td>
<td>Three median doses/0.5 × 10^6 per kg body weight</td>
<td>Intravenous</td>
<td>43</td>
<td>Increased serum albumin, cholinesterase and platelet; Decreased MELD score, prothrombin time, total bilirubin and ALT</td>
<td>[66]</td>
</tr>
<tr>
<td>UC-MSC</td>
<td>Three median doses/0.5 × 10^6 per kg body weight</td>
<td>Intravenous</td>
<td>7</td>
<td>Decreased serum alkaline phosphatase and γ-glutamyltransferase</td>
<td>[25]</td>
</tr>
<tr>
<td>UC-MSC</td>
<td>Three median doses/0.5 × 10^6 per kg body weight</td>
<td>Intravenous</td>
<td>45</td>
<td>Improvement in liver function</td>
<td>[25]</td>
</tr>
<tr>
<td>UB-MSC</td>
<td>Single median dose/1.5 × 10^7</td>
<td>Percutaneous</td>
<td>51</td>
<td>Improved QULI</td>
<td>[73]</td>
</tr>
</tbody>
</table>
of 51 patients were enrolled and transfused with $1.5 \times 10^7$ UB-MSCs percutaneously directly into parenchyma. In this study, UB-MSC therapy prolonged patients’ lives and improved their quality of life. Although only few clinical trials have been conducted, and there are overt limitations to each of these trials, it is proposed that multiple infusions (either systemic or selected artery delivery) of allogeneic MSCs ($0.5 \times 10^6$) is a viable approach in the management of liver cirrhosis.

**Future Perspectives**

Although multiple clinical trials and pilot studies have indicated to the exciting potential of the clinical utility of autologous or allogeneic stem cells in the management of liver cirrhosis, the exact reproducible therapeutic recommendation remains inconclusive. This is due to the different technical approaches across all the different studies. While it is difficult to control for the different natural histories of liver cirrhosis patients, future studies should focus on selection of homogenous groups of clinical patients. This will facilitate standardization of clinical protocols to achieve comparable and measurable endpoints. To achieve this, patient selection can be improved by using defined “inclusion and exclusion criteria” for different types or degree of severity of cirrhosis. The factors that can be used to determine the “inclusion and exclusion criteria” for different degrees of severity of cirrhosis include total bilirubin, albumin and globulin levels, Prothrombin time, CPS and MELD scores. There are 2 types of liver cirrhosis, which are broadly classified into alcoholic and non-alcoholic liver cirrhosis. Based on this classification, therapeutic strategy can be optimized for different types of cirrhosis, such as dose, mode of administration and frequency of transplantation (Figure 2).

![Figure 2](image-url)
hepatic artery showed more promising results in patients with alcoholic liver cirrhosis as compared to systemic administration. Disease-specific optimization of stem cell therapy will improve the patient life.

Based on the various studies reviewed here, $2 \times 10^8$ per kg body weight of BM-MNCs, $2 \times 10^8$ of BM-HSCs and 1 million per kg body weight of autologous or allogeneic MSCs would be a good starting infusion cell number in future studies or applications. With regards to the route of administration, the systemic transplantation (intravenous) of stem cells is the easiest approach. However since this route requires homing to the target site, the therapeutic efficiency is potentially minimized. Although HSCs and MSCs have considerable homing ability, direct infusion (hepatic artery or intrasplenic) of stem cells would enhance the liver regeneration effect. In addition, to mitigate disease progression and maintain the physiological state, multiple infusions of stem cells may improve the quality of life along with increased liver function.

It has been established that each type and source of adult stem cells has their own liver regeneration potential. In comparison to the infusion of specific stem cells, the infusion of mixed population of stem cells derived from the bone marrow may have synergistic effect in liver regeneration. For example, MSCs have been recognized as an imperative constituent of HSC niche, whereby they enhance the ability of HSCs to grow, sustain, home and differentiate by secreting various cytokines, growth factors and matrix proteins. Thus, MSCs are considered as an essential supportive scaffold for HSC in vivo. In non-obese diabetic/severe combined immunodeficiency mice, it was shown that MSCs promote the engraftment of UB-HSCs by modulating alloreactivity [67]. Another pilot study reported that the co-transplantation BM-MSC and peripheral blood stem cells was well-tolerated and improved disease prognosis [68]. Several clinical studies have demonstrated that the collective stem cell populations from the bone marrow have produced promising clinical outcomes in bone vascularization [69] and heart failure therapy [70]. However, the symbiotic relationship between HSCs and MSCs in liver regeneration has not yet been determined. No studies have been conducted to directly compare the efficacy of infusion of specific stem cells and mixed population cells in the context of liver regeneration. If a synergetic effect is proven, the optimal ratio of the mixed stem cell population needs to be determined in order to maximize clinical potential.

The bone marrow is a major reservoir for HSCs and MSCs but insufficient numbers of stem cell populations in individual patients limit the viability of cell-based therapies via intravenous, intrasplenic or the hepatic artery. To overcome this problem, ex vivo expansion of HSCs and MSCs has been studied extensively. Nevertheless, the effective optimal ratio of HSCs and MSCs has not yet been determined. One pre-clinical study reported that 1:8 to 1:16 ratio of HSCs and MSCs co-transplantation might enhance engraftment efficacy. This study also suggested that by increasing the proportion of MSCs, the engraftment efficacy was repressed [71]. Although the therapeutic efficacy of HSC and MSC co-transplantation was more significant than the individual components alone, more clinical data pertaining to safety and viability is required before effective translation into the clinic can be instituted. Nonetheless, in the near future, it is expected that once the various knowledge gaps are bridged, co-transplantation of autologous or allogeneic ex vivo expanded combination of stem cells will transform the management of liver cirrhosis.

Conflict of Interest

The authors express no conflicts of interest towards the publication of this paper.

References

39. Li Z, He C, Xiao J, Chen ZY (2013) Treating end-stage liver diseases with mesenchymal stem cells: An oak is not felled at one stroke. OA Tissue Engineering 1: 3.


